N/A N=10 Global Vascular Effects of Intermittent Pneumatic Compression-Pilot Study
Coronary Heart Disease
Primary: Brachial Flow Velocity — 21.0 cm/sec
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=9 Intermittent Pneumatic Compression to Improve Revascularization Outcome
Peripheral Arterial Disease
Primary: Walking Endurance — -14; 35 Meters
N/A N=55 Comparison of Different Intermittent Pneumatic Compression Devices for Deep Vein Thrombosis
Venous Thrombosis · Deep Vein Thrombosis
Primary: Rate of Deep Vein Thrombosis — 14; 15; 9; 12 participants — p=0.785
N/A N=407 Intermittent Pneumatic Compression in Surgical Patients at Extremely-high Risk for Venous Thromboembolism
Venous Thromboembolism · Venous Thrombosis
Primary: Number of Patients With Asymptomatic Venous Thrombosis of Lower Limbs as Detected by Duplex Ultrasound — 1; 34 Participants — p=<0.001
N/A N=52 Effect of Intermittent Pneumatic Compression on Ulcer Healing in Subjects With Secondary Lymphedema
Lymphedema
Primary: Median Time to Wound Closure at 9 Months — 141; 211 median number of days for complete heali
N/A N=36 Intermittent Pneumatic Compression in Women With Lipo-lymphedema (Lipedema With Swelling)
Lipedema · Lipolymphedema
Primary: Change in Circumferential Measurements Over Time — -0.5; -1.0; -1.3; -2.0 cm
N/A N=150 Compression Treatment Effects on Complications and Healing of Achilles Tendon Rupture
Rupture · Venous Thromboembolism · Venous Thrombosis
Primary: Venous Thromboembolic Events (VTE) — 26; 14 participants — p=0.042
N/A N=10 Effect of Neuromuscular Calf Stimulation and Intermittent Pneumatic Compression on Lower Limb Venous Hemodynamics
Intermittent Pneumatic Compression
Primary: IPC(on) Peak Velocity Change From Baseline — 6.2 cm/s
N/A N=67 Safety and Efficacy Study of a New Intermittent Pneumatic Compression Device to Treat Patients With Peripheral Arterial Disease (PAD) Stage II
Peripheral Arterial Disease
Primary: Absolute Claudication Distance (ACD) — 54.374; 0.792 Meters
Phase 2 N=11 Response to Intermittent Pneumatic Compression Therapy in Head and Neck Cancer-Related Lymphedema
Head and Neck Neoplasms · Head and Neck Lymphedema · Head and Neck Cancer
Primary: Lymph Movement Measured by ICG Lymphography. — 5; 5; 0; 0 Participants
Phase 2 N=90 Compression Device Versus 4-layer Compression System
Leg Ulcers
Primary: Safety Measured by the Number of Subjects With Adverse Events (Including Any Deterioration of Ulcer) — 33; 47 Number of Subjects with Adverse Events
N/A N=80 Evaluating the Need for Pneumatic Compression Devices
Osteoarthritis
Primary: Number of Participants With Venous Thromboembolism — 0; 3 Participants
N/A N=30 The Effect of Inelastic Compression System on Quality of Life in People With Chronic Venous Insufficiency
Chronic Venous Insufficiency
Primary: Change in the Quality of Life as Measured by CIVIQ-20 — 12.2 score on a scale
N/A N=60 Does Fluid Requirement Decrease With the Use of Pneumatic Compression Device on Lower Limbs
Fluid Overload
Primary: Heart Rate at T0 — 85.23; 88.833 beats per minute — p=.443
N/A N=20 A Hemodynamic Comparison of Stationary and Portable Pneumatic Compression Devices
Total Hip Arthroplasty
Primary: Peak Venous Velocity — 127.9; 155.7; 87.1; 86.8 cm/s
N/A N=106 Wearable Technology to Reduce Risk of DVT and Increase Patient Compliance
Orthopedic Disorder
Primary: Compliance to Prescribed Use — 67.7; 83.3 percentage of prescribed use/24hr
N/A N=81 Evaluation of a Dual Action Pneumatic Compression Device: Patient Ease of Use and Comfort
Chronic Venous Insufficiency
Primary: Ease of Use and Comfort for Subjects Using the ACTitouch System. — 70.8; 37.5; 89.2; 59.4 Percent of participants
N/A N=28 Evaluation of a Dual Action Pneumatic Compression System: Tolerance and Comfort in Patients With Venous Leg Ulcers (VLUs)
Venous Leg Ulcer · Chronic Venous Insufficiency · Venous Stasis Ulcer
Primary: Number of Participants Who Agreed With Tolerance and Comfort Questionnaire Items After Using a Dual Action Pneumatic Compression Device — 12; 8; 9; 15 Participants
N/A N=46 Intermittent Pneumatic Compression Device for Vein Dilation in Kidney Disease Patients to Enable AVF Creation (FACT)
Kidney Diseases
Primary: Vein Diameter — 1.692; 2.100 millimeters — p=0.012
N/A N=32 Leg Thermotherapy for Intermittent Claudication
Peripheral Artery Disease
Primary: Exercise Tolerance Assessed by Measuring Distance (m) Walked in 6-minutes — 388.75; 414.96; 404.29; 419.73 meters
N/A N=21 Treatment Response to Different Lymphoedema Compression Programs Using a Pneumatic Compression Device
Lower Extremity Lymphoedema · Leg Lymphoedema
Primary: Limb Volume (ml) — -197; -60; 45 ml
N/A N=204 Compression Therapy Following Endothermal Ablation
Varicose Veins
Primary: Patient's Post-procedure Pain Score Using a Visual Analogue Scale (VAS) — 18.7; 27.8 mm
N/A N=23 OsciPulse Device for the Prevention of VTE
Venous Thromboembolism · Deep Vein Thrombosis · Pulmonary Thromboembolisms
Primary: Part 1 - Subject's Response to Tolerability Questionnaire — 3; 0; 0; 0 Participants
N/A N=42 Adjuvant Benefit of NMES to Supervised Exercise in Patients With IC
Intermittent Claudication · Peripheral Vascular Disease · Lower Limb Arterial Disease
Primary: Initial Walking Distance Measured by Treadmill — 65.60; 95.50 metres
N/A N=20 Pressure Alternating Shoes
Foot Ulcer, Diabetic
Primary: Maximum Average Pressure at Baseline With Pressure Alternating Shoes, Right Foot (Before Any Cells Were Offloaded) — 118.5; 113.7; 96.6; 54.9 kPa
N/A N=21 Neuromuscular Electrical Stimulation (NMES) in Patients With Intermittent Claudication
Intermittent Claudication · Peripheral Vascular Disease
Primary: Change From Baseline in Initial Walking Distance — 64.3 metres
Phase 3 N=561 Prostaglandin E1 in Outpatients With Intermittent Claudication
Stage II Peripheral Arterial Occlusive Disease · Intermittent Claudication Fontaine Stage II PAOD
Primary: Ratio of Pain-free Walking Distance After Period 2 in Comparison With the Findings at Baseline — 2.60; 1.98 meter/meter
N/A N=20 A Study to Evaluate Lower Extremity Sleeve and Pump Device to Treat Hemiparesis
Upper Extremity Weakness · Stroke
Primary: Wearing Tolerance of the SCD and Sleeve on the Upper Extremity. — 20 Participants
N/A N=12 Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology
Bone Metastases · Musculoskeletal Cancer · Soft Tissue Sarcoma
Primary: DVT Incident Rate — 0; 0 Participants
N/A N=301 Balloon Pump Assisted Coronary Intervention Study
Coronary Artery Disease · Left Ventricular Dysfunction
Primary: Major Adverse Cardiac and Cerebrovascular Events — 23; 24 Participants